Posted by Michael Wonder on 28 Jun 2016
Proposal to list cholic acid (Cholebiol) for rare disorder
28 June 2016 - PHARMAC is seeking feedback on a proposal to list cholic acid (Cholebiol) resulting from a provisional agreement formed between Max Health Limited and PHARMAC.
The provisional agreement is the fifth that PHARMAC has reached with a bidder in a Request for Proposals we ran in 2014, related to the supply of medicines for rare disorders.
In summary, this proposal would result in cholic acid (Cholebiol) being funded in the community under Special Authority criteria and in DHB hospitals subject to restrictions for the treatment of bile acid synthesis disorders due to single enzyme defects with neonatal/infant-onset liver disease.
Listing in the Pharmaceutical Schedule would occur after Medsafe approval of the pharmaceutical.
